High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 5, 2015, Pages 517-524

  Kuaban, C ^a,b   Noeske, J ^c   Rieder, H L ^d,e   Ait Khaled N ^d   Abena Foe, J L ^f   Trebucq A ^c  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b UNIVERSITY OF BAMENDA   (Cameroon)

^c International Union Against Tuberculosis and Lung Disease ^*  (France)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f National Tuberculosis Control Programme   (Cameroon)

Author keywords

Cameroon; Multidrug resistance; Short course; Treatment; Tuberculosis

Indexed keywords

ANTIEMETIC AGENT; ANTIRETROVIRUS AGENT; CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BODY MASS; CAMEROON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGLYCEMIA; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEURITIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOCIAL SUPPORT; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT DURATION; VOMITING; YOUNG ADULT; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MEDICATION COMPLIANCE; ODDS RATIO; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TIME; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CAMEROON; CLOFAZIMINE; COHORT STUDIES; CONFIDENCE INTERVALS; DEVELOPING COUNTRIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; KANAMYCIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROTHIONAMIDE; PYRAZINAMIDE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84928888056     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0535     Document Type: Article

References (18)

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PloS Med 2012; 9(8): e1001300.
3. Van Deun A, Aung K J M, Halim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
4. Aung K J M, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
6. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
7. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 2013.
8. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
9. Chang K C, Yew W W, Tam C M, Leung C C. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review and cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-4104.
10. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014.
11. Marais E, Mlambo C K, Lewis J J, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection 2014; 42: 405-413.
12. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
13. Kuaban C, Noeske J, Nyankiye E, Piubello A, Eyangoh S. Experience with a 21-month standardized regimen for the treatment of multidrug-resistant tuberculosis. 40th World Conference on Lung Health of the International Union Against Tubreculosis and Lung Disease, Cancún, Mexico, 3-7 December 2009 [Abstract PC-94308-06]. Int J Tuberc Lung Dis 2009; 13 (Suppl 1): S193-S194.
14. Sturdy A, Goodman A, José R J, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815-1820.
15. Ramma L, Ibekwe T S. Cochleo-vestibular clinical findings among drug resistant tuberculosis patients on therapy - a pilot study. Int Arch Med 2012; 5: 3.
16. Rahman S, Ecob R, Costello H, et al. Hearing in 44-45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study. BMJ Open 2012; 2: e000411.
17. Seddon J A, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling A C, Schaaf H S. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40: 1277-1286.
18. Modongo C, Sobota R S, Kesenogile B, et al. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect Dis 2014; 1471-2334/14/542.